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Desmoid-type fibromatosis (DTF) is an uncommon nonmetastatic fibrous neoplasm. Sporadic intraperitoneal DTF is
rarely described in current literature. We herein report a case of DTF of unknown cause involving the pancreatic
head. A 41-year-old man presented with recurrent epigastric pain and weight loss. An abdominal computed
tomography scan showed a well-delineated solid cystic mass inside the pancreatic head. Pylorus-preserving
pancreaticoduodenectomy was performed due to the patient’s debilitating symptoms and suspected malignancy.
The pathological examination revealed massive fibroblastic proliferation arising from the musculoaponeurotic
tissues, consistent with a diagnosis of DTF. Immunohistochemical phenotyping determined positive immunoreactivity
to vimentin and β-catenin, but negative immunoreactivity to smooth muscle actin, CD117, CD34, or S-100,
confirming the diagnosis of DTF. No local recurrence or distant metastasis was found during a 24-month follow-up.
Radical resection is recommended as first-line treatment for pancreatic DTF. Long-term follow-up studies are required
to establish the prognosis of pancreatic DTF.
Keywords: Desmoid-type fibromatosis, Desmoid tumor, Aggressive fibromatosis, Pancreatic head,
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Desmoid-type fibromatosis (DTF), also known as des-
moid tumor or aggressive fibromatosis, is a rare soft
tissue neoplasm. It is locally invasive but without meta-
static potential, and is slow-growing [1]. DTFs, which
may be extra-abdominal, of the abdominal wall, or intra-
abdominal, can arise from any fibrous connective tissues
throughout the body [2], but the great majority occur un-
predictably at sites of previous trauma, scarring, or ir-
radiation. Moreover, approximately 7.5% of DTF patients
have concomitant familial adenomatous polyposis (FAP),
especially in intra-abdominal cases [3].
DTF is more frequently reported among the pediatric
population (infantile DTF), but can occur at any age. In
children, DTFs have primarily been extra-abdominal, in-
volving the skeleton, skeletal muscle, adjacent fascia, apo-
neurosis, or periosteum. Intra-abdominal DTF (8%) is
seen more often in adults, mainly in the gastrointestinal
and genitourinary tracts [4]. Although not metastatic,* Correspondence: daicl_sj@163.com
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reproduction in any medium, provided the orDTF tends to destroy surrounding tissues and organs and
recurs frequently after radical resection.
Intra-abdominal DTFs derive primarily from mesenteric
connective tissue or the retroperitoneum [5]. These
tumors are rarely symptomatic, but encountered inciden-
tally at laparotomy. In addition, an intra-abdominal DTF
is more often observed in patients with complicating
Gardner’s syndrome or FAP [6]. In some cases, intra-
abdominal DTF has been associated with prior abdominal
surgery and resembles intraperitoneal recurrence, locore-
gional metastasis, or abscess following the radical resec-
tion of gastrointestinal malignancies [7]. The incidence of
sporadic intra-abdominal DTF is low (5%); fewer than
100 cases have been reported since the 1960s. Of these,
intra-abdominal DTF of pancreatic origin is particularly
rare, with only nine individual cases described in the
English literature since the 1980s [6-13] (Table 1).
Herein we report a patient with an isolated, sporadic,
and non-trauma-related DTF, located at the pancreatic
head and manifesting as a cystic lesion. The patient
underwent a successful curative resection and exhibited
no signs of recurrence or metastasis within a 24-month
follow-up period.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.















Surgery Adjuvant treatment Recurrence Follow-up
Roggli et al.
(1980) [6]
M 0.3 Tachypnea, fever,
anorexia, weight loss
NA Solid Diffuse NA None Biopsy None NA DOD 7 days
Bruce et al.
(1996) [7]
M 38 Abdominal ache NA Solid Tail 5 × 4.5 × 2.1 Partial pancreatectomy Resection NA No ANED 24 months
Sedivy et al.
(2002) [8]
F 68 Weight loss, nausea Normal Solid Head 1.5 Pancreatic biopsy Resection NA NA NA
Nursal et al.
(2003) [9]
F 25 Epigastric pain NA Solid Tail 8.5 × 5.0 None Biopsy Symptomatic NA NA
Nursal et al.
(2003) [9]
M 39 Epigastric pain NA Solid Tail 7.5 × 4.0 None Biopsy Symptomatic NA NA
Pho et al.
(2005) [10]a
M 17 Epigastric pain,
weight loss
NA Cystic Tail 2.8 × 4.2 None Resection Sulindac, tamoxifen,
methotrexate, vinblastine
Yes AWD 24 months
Weiss et al.
(2006) [11]
M 63 Epigastric pain,
abdominal fullness
Normal Solid Tail 6.5 × 5.3 Partial pancreatectomy Resection None No ANED 9 months
Amiot et al.
(2008) [12]
F 51 Epigastric pain,
weight loss
Normal Cystic Tail 6 None Resection None No ANED 12 months
Polistina et al.
(2010) [13]
M 68 None Normal Cystic Tail 5 None Resection None No ANED 60 months
Present study
(2013)
M 41 Epigastric pain,
weight loss
Normal Cystic Head 1.9 None Resection None No ANED 24 months
aAll cases were sporadic except for one patient with complicating FAP reported by Pho et al. [10]. CT, computed tomography; NA, not available; ANED, alive with no evidence of disease; AWD, alive with disease;
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Case presentation
A 41-year-old Han Chinese male non-smoker was re-
ferred to our surgical unit due to a six-month history of
progressive epigastric pain and loss of weight. He denied
any radiating pain, nausea, or vomiting. His past medical
history showed a healed pulmonary tuberculosis and
excision of a neck lipoma, 15 and 10 years previously,
respectively. No history of prior abdominal trauma or
surgery was noted. The patient had concomitant essential
hypertension, but received no antihypertensive treat-
ment. No family history was reported that was suggestive
of any genetic disease.
His physical examination was clinically insignificant.
The liver function test was normal except for elevations
in conjugated and unconjugated bilirubin: total 60.2
μmol/L (reference limits, 3.4 to 20.5 μmol/L), conjugated
19.3 μmol/L (0 to 8.6 μmol/L), and unconjugated
40.9 μmol/L (3.4 to 11.9 μmol/L). The levels of serum
tumor markers were within normal limits: carcinoem-
bryonic antigen, 2.5 ng/mL (0 to 5 ng/mL); carbohydrate
antigen 19 to 9, 30.3 IU/mL (0 to 37 IU/mL); and
α-fetoprotein antigen, 4.2 IU/mL (0 to 9 IU/mL).
An abdominal computed tomography (CT) scan re-
vealed a 1.9-cm solid cystic mass in the pancreatic head,
with no signs of vascular or visceral invasion (Figure 1a).
The pancreatic mass was well-delineated but not encap-
sulated, with no evidence of local invasion or metastasis.
Magnetic resonance imaging (MRI) and endoscopic
ultrasonography (EUS) were subsequently ordered to
further characterize the anatomical relationship of the
pancreatic head mass to the surrounding organs. On
MRI scan, a focal cystic mass was found in the uncinateFigure 1 Imaging investigations of the pancreatic head DTF (indicate
(c) MRCP, and (d) EUS.process of the pancreas, showing low signal intensity on
T1- and T2-weighted images (Figure 1b). The peritu-
moral tissue exhibited a hyperintense shadow in an an-
nular shape on a T1-weighted image, whereas this
shadow was partially hyperintense without any signifi-
cant enhancement on a T2-weighted image. The de-
scending segment of the duodenum showed a diffuse
thickening with potent contrast enhancement on the in-
ternal wall and the mucosal lining. Magnetic resonance
cholangiopancreatography (MRCP) indicated that the
intrahepatic duct, the common bile duct, and the main
pancreatic duct were all moderately dilated (Figure 1c).
Furthermore, on EUS a well-demarcated, hypoechoic le-
sion located in the pancreatic head with a normal sur-
rounding region was observed (Figure 1d).
A diagnosis of suspected intraductal papillary mucin-
ous neoplasm or other cystic neoplasm of the pancreas
was made for this pancreatic tumor. Elective surgical re-
section was scheduled as this pancreatic tumor was
symptomatic with a suspected diagnosis. During laparo-
tomic exploration, the mass appeared to be localized
completely inside the pancreatic head, without any
locoregional invasion or lymph node involvement. On
gross pathology the tumor appeared as a grayish, dense,
cystic, single-cavity mass, free of capsule, without necro-
sis or hemorrhage. In view of a suspected pancreatic
neoplasm, a Traverso-Longmire procedure was per-
formed. The pylorus and spleen were preserved along
the lymph node dissection of the peripancreatic region
and the celiac axis. The surgical procedure was unevent-
ful and lasted approximately six hours. The volume of
intraoperative blood loss was approximately 1000 mL,
and the patient received a 400-mL plasma transfusion.d by the arrow) using (a) abdominal CT scan, (b) MRI scan,
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(POD) 7 but developed an infected intra-abdominal
hematoma on POD 13. This condition resolved with
antimicrobial therapy as well as peritoneal irrigation and
drainage. Oral intake was initiated on POD 18, and the
patient was discharged from the hospital on POD 21.
The histological examination confirmed a clean re-
section margin. Histological sections showed a large
number of spindle-shaped cells, with a regular nuclear
pattern within a background of massive collagen fibers.
The peritumoral parenchymal tissue was edematous and
infiltrated by tumor cells and a small number of inflam-
matory cells (Figure 2a). No marked cell death or mitosis
was observed inside the tumor tissue. The cystic compo-
nent was found to be a dilated pancreatic duct filled with
pancreatic secretion. The duodenal muscularis propria,
the locoregional lymph nodes, and the pancreatic plexus
were tumor-free.
Further immunohistochemical analysis was ordered to
differentiate uncommon gastrointestinal tumors of mes-
enchymal or neural origin; that is, DTF, fibrosarcoma,
gastrointestinal stromal tumor, and neurosarcoma. The
analysis revealed that the tumor cells were immunoposi-
tive for vimentin (Figure 2b) and β-catenin (Figure 2c),
but immunonegative for smooth muscle actin, S-100,
CD117, and CD34. These pathological features were
consistent with a diagnosis of intra-abdominal DTF [3].
The patient received no adjuvant therapy after surgery.
He was followed-up regularly at the outpatient clinic
using routine hematological and biochemical tests, as
well as abdominal CT scan. He exhibited good health
and complained of no discomfort. The total bilirubin
level returned to normal after the resection. No signs of
local recurrence or distant metastases were identifiable
on abdominal CT scan by the last scheduled follow-up
visit at 24 postoperative months.
Discussion
Pancreatic tumors are usually (approximately 95%) pri-
mary cancers of exocrine origin, namely, adenocarcinomas;Figure 2 Histopathology of the pancreatic head DTF: (a) histology (20
scale bar = 50 μm) showing positive immunoreactivity against (b) vimthe remainder arise from neuroendocrine cells. Pancre-
atic DTFs are extremely rare and encountered inciden-
tally in surgical practice. Only nine previous cases of
pancreatic DTFs have been reported within the last three
decades in the English medical literature [6-13] (Table 1).
Of these nine cases, all occurred in middle-aged patients
except for one infant [6]. Three patients had cystic pan-
creatic tumors and one patient had concomitant FAP.
Seven of the pancreatic DTFs were located in the pancre-
atic tail, one in the head, and one case was diffuse
throughout the pancreas. To the best of our knowledge,
our patient is the second reported case of DTF of the
pancreatic head in the English literature.
The etiology of intra-abdominal DTF is unknown. The
risk factors include being female, genetic mutation, posi-
tive family history, and previous history of abdominal
surgery. Because women are more prone to sporadic
intra-abdominal DTF than men, (a female-to-male ratio
of 2:1 to 5:1), estrogen might have a pathogenetic role
[14]. However, for diagnosed pancreatic DTF in particu-
lar, the literature review and our report identified seven
males and three females.
FAP is frequently associated with intra-abdominal
DTF, but only one pancreatic DTF patient was reported
to have concomitant FAP in the current literature [10].
Two siblings harbored pancreatic and pelvic DTFs in the
absence of FAP [9].
A somatic mutation in the genes 3′-adenomatous
polyposis coli (APC) or β-catenin (CTNNB1) is the most
significant risk factor for intra-abdominal DTF in FAP
patients [15,16]. The protein APC assists in the regula-
tion of cellular β-catenin, which is implicated in the
process of wound healing and fibroproliferation. APC
and β-catenin are both members of the Wnt signaling
pathway, which may be aberrantly expressed in DTF, irre-
spective of familial or sporadic origin [17]. The transloca-
tion of cytoplasmic β-catenin into the nucleus activates
the expression of T-cell factor, which in turn upregulates
the expressions of downstream genes such as cytochrome
oxidase 2 (COX2), platelet-derived growth factor (PDGF),0×, scale bar = 50 μm) and (b, c) immunohistochemistry (200×,
entin and (c) β-catenin.
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motility receptor (RHAMM), and retinoblastoma 1 (RB1)
[18]. These genetic mechanistic factors may underlie the
variable biological behavior and clinical course of DTF.
No specific genetic study has investigated such suscepti-
bility in pancreatic DTF, as only a few individual cases
have been reported.
Previous abdominal surgery is said to initiate the pro-
liferation of fibrous tissue and is therefore implicated in
the occurrence and recurrence of intra-abdominal DTF.
However, of the reported pancreatic DTF patients, only
two had undergone previous abdominal surgery, one of
whom developed a sporadic DTF at the pancreatic su-
ture line [7], and the other a DTF of the pancreatic
stump following a distal pancreatectomy for pancreatic
neuroendocrine tumors [11]. Our case is sporadic and
not associated with FAP or abdominal surgery.
DTF is characterized by a highly variable and unpre-
dictable clinical course of tumor growth, stabilization,
and occasionally even spontaneous regression in the
absence of medical intervention [19]. DTF-associated
symptoms depend on the location of the tumor. Intra-
abdominal DTF is usually asymptomatic or symptoms
are non-specific, such as abdominal discomfort or pain
and weight loss. If blood vessels, the gastrointestinal
tract, or the urinary tract is involved, a patient may
present with symptoms of compression or obstruction.
Like pancreatic cancer, pancreatic DTF is usually silent
in terms of clinical signs. Epigastric pain, the most
common complaint, seldom radiates to the back as in
pancreatic cancer. Weight loss is also often seen in pan-
creatic DTF patients due to chronic aversion to food.
Painless jaundice, a classic manifestation of pancreatic
head cancer, is rarely seen in patients with pancreatic
head DTF as it usually does not obstruct the common
bile duct [8]. However, our patient had a mild elevation
in bilirubin which returned to normal after radical resec-
tion. In most cases, laboratory findings and levels of
serum tumor markers stay within normal limits.
A confirmed diagnosis of sporadic intra-abdominal
DTF prior to surgery is very unlikely, while a tentative
diagnosis is mainly based on clinical suspicion combined
with medical imaging evaluation. A history of FAP may
raise the possibility of intra-abdominal DTF, although
pancreatic DTF is usually sporadic. Medical imaging
evaluation is important for characterizing the location of
pancreatic DTF in relation to the surrounding tissues
and organs (including the pylorus, duodenum, common
bile duct, and spleen) and for determining its resectabil-
ity. On imaging studies, pancreatic DTF usually mani-
fests as a well-defined solid or solid cystic lesion. On
ultrasonography, it is homogeneous and hypoechoic; on
CT scan, it appears as hypodense soft tissue; and on
MRI, signal intensity is low. The tumor is expected to bemildly enhanced in the presence of contrast media, as it
consists essentially of over-proliferation of fibrous tissue.
EUS is very useful for visually defining the pancreatic
tumor located in the pancreatic head, and to determine
whether the major vessels and the duodenum are in-
filtrated by the tumor. Additionally, EUS allows fine-
needle aspiration biopsy for cytological examination of
superficially located tumors [20,21]. In the present case
it was difficult to differentiate pancreatic DTF from pan-
creatic cystadenocarcinoma on CT/MRI scan, although
contrast images suggested the presence of a primary
pancreatic tumor.
The typical histology of DTF shows regular fibroblasts
and fibrocytes in a well-oriented pattern, but also with
an infiltrative growth pattern within a background of
massive collagen bundles. However, it is histologically
challenging to differentiate pancreatic DTF from other
uncommon pancreatic tumors such as low-grade fibro-
sarcoma, neuroendocrine tumor, and gastrointestinal
stromal tumor. DTF is sometimes thought to be a po-
tential sarcoma due to its aggressive growth and local in-
vasion, but pathologic mitosis or metastasis is very
unlikely [22].
Immunohistochemistry against specific cell markers of
various origins is a very effective diagnostic tool for the
differentiation of pancreatic tumors. Pancreatic DTF ex-
presses the markers for mesenchymal cells (vimentin)
but not markers for stromal cells (CD117 and CD34) or
neural cells (S-100). β-catenin immunohistochemistry is
reported to be useful for distinguishing deep DTF from
other benign or malignant fibroblastic and myofibro-
blastic lesions [22]. Thus, the pathological diagnosis of
pancreatic DTF is established and that of pancreatic
gastrointestinal stromal tumor can be excluded, based
on the histological and immunohistochemical findings.
Multimodal therapy has been reported for the treat-
ment of intra-abdominal DTF, including pancreatic DTF.
Watching and waiting is an acceptable option for pa-
tients with asymptomatic or minimally symptomatic
DTF, as it is a non-metastatic and slow-growing tumor.
However, surgical intervention seemed mandatory in our
case as the presence of pancreatic DTF was seriously
compromising the quality of life of this patient, and its
obscure nature made it potentially life-threatening.
The mainstay of pancreatic DTF treatment is radical
resection. In most previous reports, patients underwent
distal pancreatectomy or pancreaticoduodenectomy, ex-
cept for three patients who received only a tumor bi-
opsy. The primary concern of the physician regarding
surgical resection is the high likelihood of local recur-
rence: the reported recurrence rate of DTF after resec-
tion is 19 to 77% [23], and is higher in patients with
complicating FAP or Gardner’s syndrome. A recurrent
DTF may be resectable but is associated with a greater
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formed. A clean resection margin contributes favorably
to a reduced recurrence rate, as shown by clinicopatho-
logical data [24].
Alternative or adjuvant therapies have also been pro-
posed for the management of intra-abdominal DTF.
Non-steroidal anti-inflammatory drugs (NSAIDs) were
reported to successfully downsize a pelvic DTF in a man
with complicating lower limb vascular compression [25].
Hormonal therapy using non-steroidal benzothiophene
(tamoxifen or raloxifen) effectively obtained a complete
or partial response in 13 intra-abdominal DTF patients
with complicating FAP [26]. Other treatment options
include chemotherapy (vinblastine, methotrexate, doxo-
rubicin, and dacarbazine) [27], interferon [28], and ir-
radiation therapy [29]. These modalities are mainly used
if radical resection is determined to be unfeasible or mu-
tilating. Imatinib, a targeted receptor tyrosine kinase in-
hibitor used for treating gastrointestinal stromal tumor,
has also been attempted for the treatment of DTF after
multiple cycles of chemotherapy [30]. In current litera-
ture, only one pancreatic DTF patient with complicating
FAP received NSAID and tamoxifen, as well as chemo-
therapy with methotrexate and vinblastine, in a case of
local recurrence following surgical resection [10]. This
suggests that curative resection may be adequate for the
treatment of pancreatic DTF if not complicated with
FAP.
The prognosis of pancreatic DTF is not known. Recur-
rence after curative resection has not been observed dur-
ing mid- and long-term follow-up, except for a single
patient with a congenital generalized fibromatosis [10].
A favorable survival outcome has been shown in most
cases - almost 100% for overall survival and > 80% for
progression-free survival at five years [31]. Severe pain
or narcotic dependency, tumor size > 10 cm, and need
for total parenteral nutrition are negatively associated
with survival [32]. Most reported pancreatic DTF pa-
tients survived, disease-free. Our patient has been
followed-up for 24 postoperative months and remains
free of disease at the preparation of this manuscript,
consistent with previous reports.
Conclusion
In conclusion, sporadic pancreatic DTF is a rare non-
metastatic soft tissue tumor that can be locally quite de-
structive, and in our case, debilitating. Initial diagnosis is
mainly based on clinical suspicion and medical imaging.
The diagnosis is confirmed via immunohistochemistry to
differentiate DTF from other uncommon soft tissue tu-
mors originating from the pancreas. Radical resection
with a clean margin is recommended as the first-line treat-
ment for DTF, although FAP patients are more prone to
recurrence following surgical resection. Adjuvant therapiesmay be effective for unresectable or recurrent DTF.
Long-term prognosis is currently unknown, and a regular
follow-up is essential.
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